Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07500259 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC

Study acronym: COLOPan
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 1, 2026 to Sep 11, 2026
    • Eligibility criteria expanded, about 8 words
  2. Start date: May 1, 2026 to Jul 1, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform in colorectal cancer and pancreatic ductal adenocarcinoma patients. It combines genomic sequencing with in vitro functional drug testing using patient-derived spheroids/organoids.
Trial Details
NCT Number NCT07500259
Lead Sponsor Luxembourg Institute of Health
Collaborators: Hopitaux Robert Schuman
Conditions
(from sponsor)		 Colorectal Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Related terms Colorectal Neoplasms
Enrollment 188 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov